Clinuvel ADS to Begin Trading on Nasdaq Global Select Market
CUVL sits 17% above its 52-week low of $5.98 on elevated volume (1.9× avg).
Summary
Clinuvel Pharmaceuticals announced its ADS will commence trading on the Nasdaq Global Select Market under ticker CUVL, upgrading from OTC-traded ADRs. No new capital or shares are being issued.
Key Events · Corporate Governance and Compliance · CUVL
-
Nasdaq Uplisting
ADS expected to commence trading on Nasdaq Global Select Market under ticker CUVL, upgrading from OTC-traded ADR (CLVLY).
-
Regulatory Milestones
SEC declared 20-F Registration Statement effective on July 17, 2026; Nasdaq approved the listing.
-
No Dilution
Company explicitly states no capital raise or new share issuance as part of the ADS upgrade.
-
Strategic Shift
Chairman cites a gradual shift of the business toward North America as the company matures.
Analysis · CUVL · Unknown
Clinuvel's American Depositary Shares will start trading on the Nasdaq Global Select Market under ticker CUVL, upgrading from the OTC-traded ADR (CLVLY). The SEC declared the 20-F effective on July 17, and Nasdaq approved the listing. No new capital is being raised and no new shares are being issued as part of this upgrade. The move to a major U.S. exchange increases visibility and accessibility for U.S. investors, potentially broadening the shareholder base and improving liquidity. The company emphasizes a strategic shift toward North America as it matures.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CUVL was trading at $7.02 on NASDAQ in the Unknown sector, with a market capitalization of approximately $354.7M. The 52-week trading range was $5.98 to $9.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.